Innovent to present multiple r&d results of general biomedicine pipeline at the 34th eadv congress 2025

San francisco and suzhou, china , sept. 15, 2025 /prnewswire/ -- innovent biologics, inc. ("innovent") (hkex: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, announces that it will present multiple research results at the 34th european academy of dermatology and venereology (eadv) congress 2025 in paris, france from september 17-20.
GM Ratings Summary
GM Quant Ranking